ImpactOS
See an example

CSL

Companies and groups · Australia

In these lists: Medicines

Declared lobbying cost
€600,000 – €699,999 Financial year 07/2024-06/2025
Commission meetings
3
Full-time staff on EU lobbying
1.55
European Parliament access passes
3
Registered since
17 Nov 2020
Public records onlyWhat this means

Every profile, record and figure comes from documents published by EU institutions, national authorities, courts, ethics bodies, the EU Transparency Register or established news outlets. We use no leaks, private data or anonymous tips. AI helps us gather and cross-check sources but never decides anyone's guilt: each record keeps its exact legal status and links to its source, so you can check it yourself

Registering is a legal transparency duty, not a sign of wrongdoing. Budgets and meetings show access, not influence on any particular decision. Register figures as declared on 30 Jun 2026

Fields of interest

Budget, Competition, Digital economy and society, External relations, Foreign affairs and security policy, Humanitarian aid and civil protection, Institutional affairs, Public health, Research and innovation, Single market, Taxation, Trade

Medicines and food topics they name

EU medicines law, Critical medicines, Health technology assessment

EU laws and policies they declare following15
  • Critical Medicines Act
  • Public Procurement Directive
  • Biotech Act
  • Life Sciences Strategy
  • Pharmaceutical Strategy (including OMP legislation)
  • SoHO legislation
  • Preparedness and Medical Countermeasures
  • Stockpiling Strategy
  • Trade Policy
  • Open Strategic Autonomy
  • EU Rare Disease Action Plan
  • Cross-border healthcare
  • European Health Data Space
  • Health Technology Assessment
  • EU competitiveness

Meetings with the Commission

Meetings with Commissioners or their Cabinets since 1 December 2024, as the Commission publishes them

  1. With the Commissioner

    Olivér Várhelyi

    Pharmaceuticals

    Published record
  2. With the Cabinet

    Olivér Várhelyi

    Pharmaceuticals

    Published record
  3. With the Cabinet

    Ursula von der Leyen

    Current policy challenges and opportunities

    Published record

Official entries

Checked against sources on 11 Nov 2026